Fang Shunzheng, Zhang Bin, Xiang Wei, Zheng Liujie, Wang Xiaodong, Li Song, Zhang Tongyi, Feng Daibo, Gong Yunquan, Wu Jinhui, Yuan Jing, Wu Yaran, Zhu Yizhen, Liu Enli, Ni Zhenhong
School of Pharmacy, Medicinal Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical University, Taiyuan, 030001, China.
State Key Laboratory of Trauma, Burns and Combined Injury, Department of Rehabilitation Medicine, Daping Hospital, Army Medical University, Chongqing, 400022, China.
Chin Med. 2024 Feb 15;19(1):25. doi: 10.1186/s13020-024-00899-w.
Osteoarthritis (OA) is the most prevalent degenerative musculoskeletal disease, severely impacting the function of patients and potentially leading to disability, especially among the elderly population. Natural products (NPs), obtained from components or metabolites of plants, animals, microorganisms etc., have gained significant attention as important conservative treatments for various diseases. Recently, NPs have been well studied in preclinical and clinical researches, showing promising potential in the treatment of OA. In this review, we summed up the main signaling pathways affected by NPs in OA treatment, including NF-κB, MAPKs, PI3K/AKT, SIRT1, and other pathways, which are related to inflammation, anabolism and catabolism, and cell death. In addition, we described the therapeutic effects of NPs in different OA animal models and the current clinical studies in OA patients. At last, we discussed the potential research directions including in-depth analysis of the mechanisms and new application strategies of NPs for the OA treatment, so as to promote the basic research and clinical transformation in the future. We hope that this review may allow us to get a better understanding about the potential bioeffects and mechanisms of NPs in OA therapy, and ultimately improve the effectiveness of NPs-based clinical conservative treatment for OA patients.
J Ethnopharmacol. 2022-10-28
Curr Issues Mol Biol. 2025-6-11
Small. 2025-4
Pharmaceuticals (Basel). 2025-2-21
Front Pharmacol. 2024-10-30
Signal Transduct Target Ther. 2023-10-19
Nat Rev Drug Discov. 2023-11
J Orthop Surg Res. 2023-3-27
Front Pharmacol. 2022-11-10
Arthritis Res Ther. 2022-8-18